Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide

REPAMET 2: Observational Study of the Switch From Metformin Monotherapy to Bitherapy With Metformin and Repaglinide

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00745433

Acronym

REPAMET 2

Enrollment

906

Registered

2008-09-03

Start date

2008-01-31

Completion date

2009-03-31

Last updated

2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this observational study is to investigate the efficacy (e.g. glycemic control) and safety (e.g. hypoglycemic episodes) when adding repaglinide to a monotherapy of metformin in type 2 diabetic patients under normal clinical practice

Interventions

DRUGrepaglinide

Start dose and frequency at the discretion of the physician following clinical practice

DRUGmetformin

Start dose and frequency at the discretion of the physician following clinical practice

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * Metformin monotreatment * HbA1c greater than 7% * Treatment according to SPC * Informed consent obtained

Exclusion criteria

* Any contraindication to the use of repaglinide (according to the SPC)

Design outcomes

Primary

Measure	Time frame
HbA1c	After 12-20 weeks.

Secondary

Measure	Time frame
PPG	After 12-20 weeks.
Number of hypoglycemic events	After 12-20 weeks.
Variability in FPG (Fasting Plasma Glucose)	After 12-20 weeks.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026